CG 400549

Drug Profile

CG 400549

Alternative Names: CG400549; Enoyl reductase inhibitors - CrystalGenomics; ERCG 0549; FabI inhibitor (CG400549) - CrystalGenomics

Latest Information Update: 22 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CrystalGenomics
  • Class Antibacterials; Pyridines; Small molecules; Thiophenes
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Bacterial infections

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • Phase I Vancomycin-resistant Staphylococcus aureus infections
  • Preclinical Staphylococcal infections

Most Recent Events

  • 22 Jun 2015 Clinical development is ongoing
  • 07 Jan 2013 Efficacy and adverse events data from a phase IIa trial in Methicillin-resistant Staphylococcus aureus infections released by CrystalGenomics
  • 31 Oct 2012 CrystalGenomics completes a phase IIa trial in Methicillin-resistant Staphylococcus aureus infections in USA (NCT01593761)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top